Introducing APOA1 as a key protein in COVID-19 infection: a bioinformatics approach
Gastroenterology and Hepatology from Bed to Bench,
20 September 2020
Aim: Introducing possible diagnostic and therapeutic biomarker candidates via the identification of chief dysregulated proteins in COVID-19 patients is the aim of this study.
Background: Molecular studies, especially proteomics, can be considered as suitable approaches for discovering the hidden aspect of the disease.
Methods: Differentially expressed proteins (DEPs) of three patients with demonstrated severe condition (S-COVID-19) were compared to healthy cases by a proteomics study. Cytoscape software and STRING database were used to construct the protein-protein interaction (PPI) network. The central DEPs were identified through topological analysis of the network. ClueGO+CluePedia were applied to find the biological processes related to the central nodes. MCODE molecular complex detection (MCODE) was used to discover protein complexes.
Results: A total of 242 DEPs from among 256 query ones were included in the network. Centrality analysis of the network assigned 16 hub-bottlenecks, nine of which were presented in the highest-scored protein complex. Ten protein complexes were determined. APOA1 was identified as the protein complex seed, and APP, EGF, and C3 were the top hub-bottlenecks of the network. The results specify that up-regulation of C3 and down-regulation of APOA1 in urine play a role in the stiffness in respiration and, accordingly, the severity of COVID-19. Moreover, dysregulation of APP and APOA1 could both contribute to the possible adverse effects of COVID-19 on the nervous system.
Conclusion: The introduced central proteins of the S-COVID-19 interaction network, particularly APOA1, can be considered as diagnostic and therapeutic targets related to the coronavirus disease after being approved with complementary studies.
Keywords: urine proteome, COVID-19, protein interaction mapping, biomarkers, biological process.
(Please cite as:Zamanian Azodi M, Arjmand B, Zali AR, Rezaei Tavirani M, Razzaghi MR. Introducing APOA1 as a key protein in COVID-19 infection: a bioinformatics approach. Gastroenterol Hepatol Bed Bench 2020;13(4):367-373).
- urine proteome, COVID-19, protein interaction mapping, biomarkers, biological process.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-4.
Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020:1-13.
Liu Y, Yan L-M, Wan L, Xiang T-X, Le A, Liu J-M, et al. Viral dynamics in mild and severe cases of COVID-19.Lancet Infect Dis 2020;30232-2.
Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL, et al. Smell dysfunction: a biomarker for COVID‐19. Int Forum Allergy Rhinol 2020;10:944-50.
Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020;368:473-4.
D'Alessandro A, Thomas T, Dzieciatkowska M, Hill RC, Francis RO, Hudson KE, et al. Serum proteomics in COVID-19 patients: Altered coagulation and complement status as a function of IL-6 level. J Protoeme Res 2020.
Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 2020;115-773.
Velavan TP, Meyer CG. Mild versus severe COVID-19: laboratory markers. Int Infect Dis 2020;304-7.
Li H, Xiang X, Ren H, Xu L, Zhao L, Chen X, et al. SAA is a biomarker to distinguish the severity and prognosis of Coronavirus Disease 2019 (COVID-19). J Infect 2020;80:646-55.
Naicker S, Yang CW, Hwang SJ, Liu BC, Chen JH, Jha V. The Novel Coronavirus 2019 epidemic and kidneys. Kidney Int 2020;97:824-8.
Li Y, Wang Y, Liu H, Sun W, Ding B, Zhao Y, et al. Urine Proteome of COVID-19 Patients. MedRxiv 2020.
Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 2010;27:431-2.
Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic acids Res 2015;43:447-52.
Assenov Y, Ramírez F, Schelhorn SE, Lengauer T, Albrecht M. Computing topological parameters of biological networks. Bioinformatics 2008;24:282-4.
Abdi S, Azodi MZ, Rezaei-Tavirani M, Razzaghi M, Heidari MH, Baghban AA. Differentiation of H. pylori-negative and positive gastric cancer via regulatory network analysis. Gastroenterol Hepatol Bed Bench 2020;13:161-7.
Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC bioinformatics 2003;4:1-27.
Bindea G, Galon J, Mlecnik B. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics 2013;29:661-3.
Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 2009;25:1091-3.
Gates B. Responding to Covid-19—a once-in-a-century pandemic? N Engl J Med 2020;382:1677-9.
Messner CB, Demichev V, Wendisch D, Michalick L, White M, Freiwald A, et al. Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection. Cell Systems 2020;11-24.
Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell 2020;182:59-72.
Whetton AD, Preston GW, Abubeker S, Geifman N. Proteomics and informatics for understanding phases and identifying biomarkers in COVID-19 disease. J Proteome Res 2020.
Wang H, Hou X, Wu X, Liang T, Zhang X, Wang D, et al. SARS-CoV-2 proteome microarray for mapping COVID-19 antibody interactions at amino acid resolution. bioRxiv 2020;1-15.
Eimer WA, Kumar DKV, Shanmugam NKN, Rodriguez AS, Mitchell T, Washicosky KJ, et al. Alzheimer’s disease-associated β-amyloid is rapidly seeded by herpesviridae to protect against brain infection. Neuron 2018;99:56-63.
Devanand D. Viral hypothesis and antiviral treatment in Alzheimer’s disease. Cur neurol neurosci Rep 2018;18:1-13.
Bourgade K, Dupuis G, Frost EH, Fülöp Jr T. Anti-viral properties of amyloid-β peptides. J Alzheimers Dis 2016;54:859-78.
Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther 2020;12:1-3.
Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, et al. Complement as a target in COVID-19? Nat Rev Immunol 2020;20:343-4.
Verschoor A, Brockman MA, Knipe DM, Carroll MC. Cutting edge: myeloid complement C3 enhances the humoral response to peripheral viral infection. J Immunol 2001;167:2446-51.
O'Brien KB, Morrison TE, Dundore DY, Heise MT, Schultz-Cherry S. A protective role for complement C3 protein during pandemic 2009 H1N1 and H5N1 influenza A virus infection. PLoS One 2011;6:1-8.
Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K, Leist SR, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. MBio 2018;9:1-15.
Mastaglio S, Ruggeri A, Risitano AM, Angelillo P, Yancopoulou D, Mastellos DC, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol 2020:1-4.
Stahel PF, Barnum SR. Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option. Front Immunol 2020;11:1-4.
Azukaitis K, Ju W, Kirchner M, Nair V, Smith M, Fang Z, et al. Low levels of urinary epidermal growth factor predict chronic kidney disease progression in children. Kidney Int 2019;96:214-21.
Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol 2020:1-2.
Hondermarck H, Bartlett NW, Nurcombe V. The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID‐19? FASEB BioAdvances 2020;2:296-303.
Eierhoff T, Hrincius ER, Rescher U, Ludwig S, Ehrhardt C. The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells. PLoS Pathog 2010;6:e1001099.
Yang Y, Zhu Z, Fan L, Ye S, Lou K, Hua X, et al. Low serum level of apolipoprotein A1 is an indicator of severity in patients with coronavirus disease 2019. 2020.
Wang Y, Hao J, Liu X, Wang H, Zeng X, Yang J, et al. The mechanism of apoliprotein A1 down-regulated by Hepatitis B virus. Lipids health Dis 2016;15:1-7.
Vollbach H, Heun R, Morris CM, Edwardson JA, McKeith IG, Jessen F, et al. APOA1 polymorphism influences risk for early‐onset nonfamiliar AD. Ann Neurol 2005;58:436-41.
- Abstract Viewed: 0 times
- PDF Downloaded: 0 times